Provided are a long-acting prodrug of Rasagiline, which has application in the treatment of Central Nervous System diseases such as Parkinson's disease, preparation method and use thereof. The long-acting prodrug of Rasagiline has a structure of formula (I), wherein T is absent, or T is selected fromeach of R1 and R2 is independently selected from H, D, and alkyl； W is absent, or W is selected from (CH2)n, wherein n is an integer selected from 1 to 15； X is absent, or X is selected from (CH2)m, wherein m is an integer selected from 1 to 10； Y is absent, or Y is selected from —；C(═；O)NH—；, —；NHC(═；O)—；； R3 is selected from substituted or unsubstituted C1-C30 alkyl, substituted or unsubstituted C2-C30 alkenyl, substituted or unsubstituted C2-C30 alkynyl, substituted or unsubstituted C3-C30 cycloalkyl, cholane aliphatic group, —；R3a—；C(═；O)O—；R3b, —；R3a—；OC(═；O)—；R3b, —；R3a—；C(═；O)NH—；R3b, —；R3a—；NHC(═；O)—；R3b, —；R3a—；S(═；O)1-2O—；R3b and —；R3a—；OS(═；O)1-2—；R3b.
